M&A · Healthcare · Pharmaceutical Preparations
Double Point Ventures to acquire Lumos Pharma, Inc.
Announced Oct 23, 2024 · Closed Dec 12, 2024
Deal value$38MEV $21M
Premium7.6%To unaffected price
EV / Adj. EBITDA—14.3x EV / Revenue
ConsiderationAll cash$4.25 per share
Transaction
- Acquirer
- Double Point Ventures
- Target
- Lumos Pharma, Inc. (LUMO)
- Buyer type
- Strategic
- Offer price per share
- $4.25
- Enterprise value
- $21M
- Status
- Closed Dec 12, 2024
Deal protections
- Break fee (target pays)
- —
- Reverse fee (buyer pays)
- —
- Go-shop
- No-shop
- Financing
- No financing condition
Advisors
- To the acquirer
- Not disclosed
- To the target
- Piper Sandler
Sector context · Healthcare
- Comparable deals
- 96 in the prior 24 months
- Premium
- 7.6% vs. 67.0% sector median
- EV / Adj. EBITDA
- Sector median 17.2x
- Break fee
- Sector median 3.5%
Timeline
- AnnouncedOct 23, 2024
- Tender offerNov 13, 2024
- ClosedDec 12, 2024
Valuation · fairness opinions
Liquidation$1.45$4.05
Analyst price targets$13.00$28.00
Offer $4.25
Implied value per Lumos Pharma, Inc. share by analysis, from Piper Sandler · DCF discount rate 14.2%–16.2%.